About Organisation
The European Union (EU) is a political and economic union comprising 27 member states committed to promoting peace, stability, and prosperity across Europe and beyond. Through various initiatives, the EU addresses shared challenges in health, security, environment, and economic development. The EU’s EU4Health Programme (EU4H) is its flagship funding mechanism aimed at strengthening healthcare systems, fostering innovation, and ensuring preparedness for health emergencies. One of the key priorities under this programme is to bolster readiness against chemical, biological, radiological, and nuclear (CBRN) threats. By facilitating research and innovation, the EU empowers stakeholders across sectors—scientific, medical, industrial, and governmental—to collaborate on developing cutting-edge solutions. The programme prioritizes cross-border coordination and promotes projects that not only advance medical countermeasures but also enhance collaboration among researchers, healthcare providers, security agencies, and policy makers. With a focus on medicinal products, vaccines, and therapeutics, the EU4Health initiative seeks to ensure that Europe remains at the forefront of medical innovation while safeguarding its population from emerging threats. This proactive approach aligns with the EU’s broader mission to foster resilience and respond effectively to global health challenges through science-based interventions and strategic partnerships.
About the Grant
The Innovative Medical Countermeasures for CBRN Threats Grant under the EU4Health Programme focuses on supporting advanced research for medical solutions against chemical, biological, radiological, and nuclear agents. This call, identified as EU4H-2025-HERA-PJ-1-a, targets the development of vaccines and therapeutics that address health threats for which there are currently limited or no available treatments. The grant encourages research efforts that bridge gaps between innovation, regulatory approval, and market deployment. Projects should aim to advance medical countermeasures such as antivirals, antimicrobials, monoclonal and polyclonal antibodies, antidotes, and supportive treatments like those for acute radiation syndrome and bone marrow suppression. The initiative seeks to integrate end users, healthcare professionals, and security experts early in the development process to ensure practical applicability and faster deployment. The focus is on platform approaches and threat-agnostic solutions to ensure preparedness for a wide range of CBRN emergencies, including intentional and cross-border health threats. By supporting regulatory processes and market readiness, the grant aims to expedite the translation of research into actionable treatments, ultimately strengthening Europe’s capacity to respond to health crises with timely and effective medical interventions.
Who can Apply?
The grant invites applications from a diverse range of stakeholders including secondary and higher education institutions, research organisations, hospitals, expert networks, security practitioners, end users, private companies, public bodies, and governmental authorities. Applicants must demonstrate the capacity to conduct advanced research and development related to medical countermeasures for CBRN threats. The programme encourages cross-sector collaboration and prioritizes projects that integrate both scientific expertise and practical deployment considerations. Proposed projects should involve partnerships with end users and security agencies to ensure real-world applicability and faster progression toward regulatory approval. Eligible applicants must be capable of developing medicinal products such as vaccines, antivirals, antimicrobials, and treatments for radiation exposure, among others. Projects must have clearly defined goals that align with the grant’s objective of increasing readiness to respond to chemical, biological, radiological, and nuclear emergencies. Furthermore, applicants should be prepared to contribute to the entrepreneurial ecosystem by addressing challenges related to market readiness and deployment strategies. The grant explicitly supports projects expected to progress toward market approval and practical implementation, emphasizing regulatory processes and stakeholder involvement. While there is no restriction based on geography within the EU, applicants must meet the administrative and scientific standards required by the EU4Health framework.
How to Apply?
Applications must be submitted through the EU’s official grant portal before 4 December 2025 at 17:00 CET. Interested organisations should prepare detailed project proposals outlining objectives, methodologies, and expected outcomes, including a comprehensive budget and timeline. The application must also highlight partnerships with end users and security practitioners, demonstrating how the project will advance medical countermeasures toward regulatory approval and market readiness within the 24 to 48-month project period.
Application Deadline
The deadline to submit applications is 4 December 2025 at 17:00 CET. All proposals must be completed through the EU portal before this date to be considered eligible.
Last Date To Apply
